CSIMarket


Windtree Therapeutics Inc  (WINT)
Other Ticker:  
 


 

Windtree Therapeutics Inc

WINT's Financial Statements and Analysis



Windtree Therapeutics Inc narrowed third quarter of 2023 net loss per share of $-0.86 compare to net loss per share of $-6.50 recorded in the same quarter a year ago and improved compare to net loss per share of $-1.64 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.86 $  0 Mill
$+5.64     Unch.    



Windtree Therapeutics Inc's Revenue fell by 0 % in third quarter of 2023 (Sep 30 2023) year on year, to $0 million and declined by sequentially.


Windtree Therapeutics Inc is Expected to report next financial results on March 30, 2024.

More on WINT's Income Statement



Windtree Therapeutics Inc's in thethird quarter of 2023 recorded net loss of $-4.425 million, an increase from net loss of $-4.056 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-6.601 million realized in previous quarter.

More on WINT's Growth

Windtree Therapeutics Inc Inventories
In Sep 30 2023 company's net cash and cash equivalents decreased by $-4 million

More on WINT's Cash flow Statement


Windtree Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Windtree Therapeutics Inc payed $ -2.57 cash per share, on a free-cash flow basis .

Book value fell by -49.51 % sequentially to $1.45 per share, -5.98% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ -3.45 per share from $ -3.39.

Company issued 1.12 million shares or 27.74 % in Sep 30 2023.


More on WINT's Dividends

 Market Capitalization (Millions) 2
 Shares Outstanding (Millions) 5
 Total Debt (Millions $) 0
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -25
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Windtree Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Windtree Therapeutics Inc had negative $ -2.57 cash flow per share, on a free-cash flow basis .

Book value fell by -49.51 % sequentially to $1.45 per share, -5.98% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ -3.45 per share from $ -3.39.

Company issued 1.12 million shares or 27.74 % in Sep 30 2023.


More on WINT's Balance Sheets

 Market Capitalization (Millions) 2
 Shares Outstanding (Millions) 5
 Total Debt (Millions $) 0
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -25
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Windtree Therapeutics Inc Earnings

Windtree Therapeutics Inc Emerges Strong Despite $4.69 Million Operating Shortfall



Windtree Therapeutics Inc, a biotechnology and pharmaceuticals company, has reported its financial results for the period ending September 30, 2023. The company experienced a decline in revenue and a significant net deficit, which has raised concerns among shareholders. With the upcoming financial earnings report scheduled in November 2023, investors are eagerly awaiting any signs of improvement and a potential change in the business model.
Financial Performance:
During the reporting cycle from July to September 2023, Windtree Therapeutics Inc faced several challenges in terms of its financial performance. Shareholders had not expected any improvements in the company's top-line revenue. Fur...

Windtree Therapeutics Inc. Reports Remarkable Financial Growth, Shattering Expectations in the Biotech Industry

As a stock market journalist, it's my job to analyze and interpret the financial results of various companies, even those that may be overlooked in the Biotechnology and Pharmaceuticals sector. One such company that has caught my attention is Windtree Therapeutics Inc.
According to their recent report, Windtree Therapeutics Inc has shown a significant improvement in their financial performance compared to the same period last year. Their operating deficit for the second quarter of 2023 was $-6.757 million, which is a substantial decrease from $-17.538 million in the second quarter of 2022. This is a positive sign for the company and indicates that they are taking steps towards becoming a successful leade...

Windtree Therapeutics Inc Reports Significant Improvement in Financial Performance, Reducing Operating Shortfall to $-4.191 Million in Q1 2023

Windtree Therapeutics Inc (WINT) is a biopharmaceutical company that specializes in developing new and innovative therapeutics for various medical conditions. The company recently published its earnings for the first quarter of 2023, and the results are positive compared to the first quarter of 2022. WINT reported a lower operating shortfall of $-4.191 million, compared to $-8.333 million in the previous year. This is a positive signal for the company's financial condition, and it is indicative of the company's efforts to increase its revenue sources.
As with any company in the biotechnology and pharmaceutical industry, it is crucial for WINT to be competitive to reach the next stage of growth. The compa...


Date modified: 2023-11-12T07:40:27+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com